Although several drugs have been proposed and used to treat the COVID-19 virus, but recent clinical trials have concentrated on ivermectin. It appears that ivermectin can potentially act against COVID-19 and stop the development in its infancy. The purpose of this study was to determine the effect of ivermectin on the recovery of outpatients with COVID-19. In this cross-sectional study, we compared the symptoms reduction in COVID-19 disease in two groups of patients by administering ivermectin. A total of 347 mild outpatients in the Iranian provinces of Qazvin and Khuzestan with a confirmed PCR were enrolled. The symptoms of outpatients with COVID-19 were analyzed using SPSS (V23). In this cross-sectional study, the sex ratio was 0.64 (female/male: 37.9/59.8) and most patients were under 50 years old (72.8%). The results of this study demonstrated a significant decrease in several COVID-19 disease symptoms, including fever, chills, dyspnea, headache, cough, fatigue, and myalgia in the group administered ivermectin compared to the control group. In addition, the odds ratio of the above symptoms was significantly lower in patients who received ivermectin than in patients who did not receive the drug (OR = 0.16, 95% CI = 0.09, 0.27).

尽管已经提出了几种药物并用于治疗 COVID-19 病毒，但最近的临床试验集中在伊维菌素上。伊维菌素似乎可以潜在地对抗 COVID-19 并阻止其婴儿期的发展。本研究的目的是确定伊维菌素对 COVID-19 门诊患者康复的影响。在这项横断面研究中，我们比较了两组患者服用伊维菌素后 COVID-19 疾病症状的减轻情况。伊朗加兹温省和胡齐斯坦省共招募了 347 名确诊为 PCR 的轻度门诊患者。使用 SPSS (V23) 分析了 COVID-19 门诊患者的症状。在这项横断面研究中，性别比为 0.64（女性/男性：37.9/59.8），大多数患者年龄在 50 岁以下（72.8%）。这项研究的结果表明，与对照组相比，服用伊维菌素的组中的几种 COVID-19 疾病症状显着减少，包括发烧、寒战、呼吸困难、头痛、咳嗽、疲劳和肌痛。此外，接受伊维菌素治疗的患者出现上述症状的比值比明显低于未接受伊维菌素治疗的患者（OR = 0.16, 95% CI = 0.09, 0.27）。